Locally Advanced Head and Neck Squamous Cell Carcinoma Clinical Trial
Official title:
First-line Treatment of Locally Advanced HNSCC With Double Checkpoint Blockade and Radiotherapy Dependent on Intratumoral CD8+ T Cell Infiltration (CheckRad-CD8, EudraCT NUMBER: 2017-003226-33)
First-line treatment of locally advanced HNSCC with double checkpoint blockade and radiotherapy dependent on intratumoral CD8+ T cell Infiltration.
This is a single arm, open-label, prospective, non-randomized Phase II clinical trial of locally advanced HNSCC with double checkpoint blockade and radiotherapy dependent on intratumoral CD8+ T cell Infiltration. All patients will initially be treated with the PD-L1 inhibitor Durvalumab (1500 mg q4w) and the CTLA-4 Inhibitor Tremelimumab (75 mg q4w / since Amendment 3 (01.04.2020): 300 mg absolute dose d5) and one cycle with Cisplatin (30mg/m² d1-3) and Docetaxel (75mg/m² d1). Treatment response will be evaluated clinically by endoscopy with biopsy. Changes of the CD8+ T cell density in the second biopsy compared to the first one before therapy will be used for patient selection. Patients with a stable or decreased CD8+ tumor infiltrating immune cell density or clinical progressive disease will receive standard CRT outside the trial. For these patients toxicity will be monitored until the first dose of the subsequent standard CRT. Patients with an increased CD8+ tumor infiltrating immune cell density and at least clinically stable disease will receive radioimmunotherapy with the PD-L1 Inhibitor Durvalumab and the CTLA4-Inhibitor Tremelimumab (altogether 4 doses q4w including the induction dose) followed by maintenance therapy with Durvalumab (8 additional doses q4w). The primary endpoint is feasibility. Feasibility criteria are receiving the protocol treatment until cycle 6 of antibody treatment and absence of any of the DLT defined in the protocol. A feasibility rate of ≥80% is expected. The efficacy of radioimmunotherapy and predictive character of changes of CD8+ tumor infiltrating immune cells after induction chemo-immunotherapy are further endpoints. The follow up period will be two years after the completion of radiotherapy. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05172245 -
Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer
|
Phase 1 | |
Completed |
NCT04949503 -
A Real-world Study of the Efficacy and Safety of Nimotuzumab in Combination With Chemoradiotherapy for LASCCHN
|
||
Completed |
NCT04870840 -
Image-guided Proton Therapy for the Treatment of Locally Advanced Unresectable Head and Neck Cancer
|
Phase 1 | |
Completed |
NCT04541355 -
Sodium Thiosulfate in Preventing Ototoxicity for Squamous Cell Cancer Patients Undergoing Chemoradiation With Cisplatin
|
Phase 2 | |
Recruiting |
NCT03649048 -
Low-Dose Weekly vs High-Dose Cisplatin
|
N/A | |
Recruiting |
NCT05724602 -
Radiotherapy Plus Xevinapant in Older Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma
|
Phase 2 | |
Not yet recruiting |
NCT05773079 -
Toripalimab Maintenance for Locally Advanced Head and Neck Squamous Cell Carcinoma
|
Phase 2 | |
Not yet recruiting |
NCT05861557 -
Neoadjuvant Radiotherapy Combined With Toripalimab for Locally Advanced Head and Neck Squamous Cell Carcinoma
|
Phase 2 | |
Recruiting |
NCT05527782 -
Induction Modified TPF Followed by Concurrent Chemoradiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck
|
Phase 2 | |
Recruiting |
NCT05269381 -
Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT05376553 -
Study of Cemiplimab - TP Induction Chemotherapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck
|
Phase 1 | |
Withdrawn |
NCT03875053 -
Home Sleep Apnea Machine in Evaluating Obstructive Sleep Apnea in Patients With Stage III-IV Head and Neck Cancer
|
N/A | |
Recruiting |
NCT04892173 -
NBTXR3 With or Without Cetuximab in LA-HNSCC
|
Phase 3 | |
Withdrawn |
NCT05743270 -
Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN
|
Phase 2 | |
Recruiting |
NCT06240689 -
A Prospective Randomized Controlled Study of Immune Checkpoint Maintenance Therapy After Radiotherapy and Chemotherapy for Locally Advanced Head and Neck Tumors Based on Peripheral Blood CD8Tex Detection in Peripheral Blood
|
Phase 2 | |
Suspended |
NCT04454489 -
Quad Shot Radiotherapy in Combination With Immune Checkpoint Inhibition
|
Phase 2 | |
Completed |
NCT01689194 -
Efficacy Study of Genexol-PM and Cisplatin in Locally Advanced Head and Neck Cancer
|
Phase 2 | |
Recruiting |
NCT05245682 -
Tolinapant and Radiation for Cisplatin-Ineligible, Previously Untreated, Locally Advanced Head and Neck Cancer
|
Early Phase 1 | |
Recruiting |
NCT04947241 -
Toripalimab Combined With Gemcitabine and Cisplatin Treating Resectable Locally Advanced HNSCC
|
Phase 1 | |
Recruiting |
NCT06129864 -
A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy
|
Phase 3 |